Hearing healthcare group Demant has signed an agreement to sell Oticon Medical, which provides bone anchored hearing solutions, to investment company Impilo.
Impilo focuses on investments in Nordic healthcare companies and will develop Oticon Medical into a stand-alone business.
Demant said it was selling the business “for a total contractual consideration of up to A$143 million (600 million Danish Kroner), thereby concluding the process of divesting its hearing implants business area”.
“The agreement ensures the continuity of Oticon Medical’s business operations, its sustained strong position in the market, further growth as well as investments in future innovation for the benefit of customers and patients,” Demant said in a media release on 22 October 2025.
Mr Søren Nielsen, Demant president and CEO, said he was very happy Impilo was taking over ownership of Oticon Medical as Impilo was a Nordic company that knows the healthcare and especially medtech sector very well.
“It has a long-term perspective, and I’m confident that Oticon Medical will continue to prosper under its new ownership,” he said.
“Oticon Medical is leaving Demant in good shape, as the company has delivered good growth over the years and recently enhanced its product portfolio with the launch of the flagship product, Sentio.
“Demant is committed to supporting the transition of the business for the benefit of customers, patients and employees.”
These transitional services will include jointly developing next-generation products, supplying existing and future sound processors and providing local sales and customer support as well as administrative services, until such functions are established in Oticon Medical, Demant said.
In its media release, Impilo said: “This transformative transaction represents the first investment from Impilo’s recently raised Fund II and marks the beginning of an exciting new chapter for Oticon Medical.
“Building on the company’s legacy of innovation and patient care, Impilo will support Oticon Medical in its transition to a standalone company while accelerating growth, advancing next-generation technologies, and strengthening its position as a pioneer in bone-anchored hearing solutions.”
Mr Fredrik Strömholm, Impilo managing partner, said the company was thrilled with the acquisition.
“Under Demant’s leadership, Oticon Medical has established itself as a global leader in the bone anchored hearing systems (BAHS) market, renowned for its innovation and unwavering commitment to patient care,” he said.
“This acquisition marks an exciting new chapter for Oticon Medical, positioning the company for even greater growth and long-term success. In close partnership with Demant, we look forward to investing in and accelerating the development of cutting-edge BAHS solutions to further enhance patient outcomes worldwide.”
Mr Magnus Edlund, partner at Impilo, said Oticon Medical had established itself as a leading player in the global BAHS market and had strengthened its position with the recently launched transcutaneous product, Sentio, which had already demonstrated impressive results.
“We are deeply impressed by the management team’s expertise, their ability to deliver outstanding patient support, and their unwavering commitment to improving patient outcomes,” he said.
“We look forward to our partnership with management and to the journey ahead, advancing the development of cutting-edge BAHS solutions that will further enhance the lives of patients.”
The existing management team will stay on to support the transition into a standalone entity and drive future growth.
Mr René Govaerts, Oticon Medical general manager said: “We are excited to welcome Impilo as new owner, whose ambition and purpose-driven approach align perfectly with our belief in Oticon Medical’s future.
“Together, we are well-positioned to accelerate global growth with new innovations and world-class support, capturing the vast potential in the underserved BAHS market. We look forward to continuing to deliver life-changing solutions to patients worldwide.”
The transaction is expected to take place no later than the end of Q1 2026, Demant said.
